Novo Nordisk has received European Commission marketing authorization for its Wegovy pill, giving the Danish drugmaker another significant head start over rival Eli Lilly. The approval covers adults with obesity or who
More
Advanced therapy supply chains are undergoing a fundamental transformation as regulatory expectations and patient-centric risk considerations continue to intensify across the industry. Adam Fox, Chief Quality and Regulatory Affairs Officer of Cryoport
More
Sanofi has filed two separate federal lawsuits against Moderna and Pfizer, alleging that several major Covid-19 and RSV vaccines infringe its mRNA delivery patents. The French pharmaceutical giant, listed on US markets
More
Cryoport Systems is repositioning the conversation around supply chains for advanced therapies, arguing that quality must be embedded from the ground up rather than applied as an afterthought. Adam Fox, Chief Quality
More
Merck (MRK) has announced that its flagship cancer drug Keytruda has achieved a landmark result in the treatment of a specific endometrial cancer subtype. The drug became the first PD-1 inhibitor to
More
Pharma’s third-party logistics sector is undergoing a fundamental transformation, moving well beyond its traditional role of shifting pallets through wholesale distribution chains. The industry is now contending with smaller patient populations, highly
More
Celcuity has secured FDA approval for gedatolisib, now branded as Revtorpyk, marking a significant milestone in the treatment of hormone receptor-positive, HER2-negative breast cancer. The regulator approved Revtorpyk specifically for previously treated
More
The Trump administration’s April 2026 announcement of a 100% base levy on imported APIs and patented drugs has forced a sweeping re-evaluation of pharmaceutical supply chains across the industry. Reshoring pharmaceutical manufacturing
More
AstraZeneca (AZN) has signed a global exclusive licence agreement with Dizal to acquire worldwide rights to develop and commercialise Zegfrovy, also known as sunvozertinib. The deal comprises a $600 million upfront payment
More
The pharmaceutical distribution sector is undergoing a significant transformation, driven by the need to balance highly targeted delivery models with large-scale operational demands. Modern drug supply chains are increasingly complex, requiring distributors
More